|
LM_ID
|
Common Name
|
Systematic Name
|
Species Shorthand
|
Formula
|
Mass
|
|
LMFA03010241
|
15-deoxyprostaglandin J3
|
11-oxo-5Z,9Z,12E,14E,17Z-prostatetraenoic acid
|
FA 20:7;O
|
C20H26O3
|
314.188195
|
|
LMFA08020298
|
1-tauro-dinor-PGE1
|
N-tauro-9,13-dihydroxy-7-oxo-dinorprosta-11-enoate
|
NAT 18:3;O3
|
C20H35NO7S
|
433.213426
|
|
LMFA08020299
|
1-tauro-tetranor-PGE1
|
N-tauro-9,13-dihydroxy-7-oxo-tetranorprosta-11-enoate
|
NAT 16:3;O3
|
C18H31NO7S
|
405.182126
|
|
LMFA08020300
|
1-tauro-dinor-PGE2
|
N-tauro-9,13-dihydroxy-7-oxo-dinorprosta-3Z,11E-dienoate
|
NAT 18:4;O3
|
C20H33NO7S
|
431.197776
|
|
LMFA03060121
|
Okeanic acid A
|
11S,14R,15S-trihydroxyeicosa-5Z,8Z,12E,17Z-tetraenoic acid
|
FA 20:4;O3
|
C20H32O5
|
352.224975
|
|
LMFA03110348
|
8-isoPGF2alpha glucuronide
|
9S,11R,15S-trihydroxy-5Z,13E-prostadienoyl glucuronide -cyclo[8S,12R]
|
|
C26H42O11
|
530.272715
|
|
LMFA03110349
|
5-epi-5-F2t-IsoP glucuronide
|
5R,9S,11R-trihydroxy-6E,14Z-prostadienoyl glucuronide -cyclo[8S,12R]
|
|
C26H42O11
|
530.272715
|
|
LMFA03120062
|
12-O-deacetylclavulone I
|
methyl 7S-acetoxy-9-oxo-12S-hydroxy-5Z,10Z,13Z-prostatrienoate-cyclo[8R,12]
|
FA 23:6;O4
|
C23H34O6
|
406.235540
|
|
LMFA03120063
|
clavulone I-15-one
|
methyl 4R-acetoxy-9,15-dioxo-5Z,7E,10Z,13E-prostatetraenoate-cyclo[8,12]
|
FA 25:9;O6
|
C25H32O8
|
460.209720
|
|
LMFA03110350
|
5-epi-8,12-iso-iPF3alpha-VI
|
(E,5R)-7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-[(2Z,5Z)-octa-2,5-dienyl]cyclopentyl]-5-hydroxyhept-6-enoic acid
|
FA 20:4;O3
|
C20H32O5
|
352.224975
|
|
LMFA03110351
|
8,12-iso-iPF3alpha-VI
|
(E,5S)-7-[(1R,2S,3R,5S)-3,5-dihydroxy-2-[(2Z,5Z)-octa-2,5-dienyl]cyclopentyl]-5-hydroxyhept-6-enoic acid
|
FA 20:4;O3
|
C20H32O5
|
352.224975
|
|
LMFA03010243
|
Tetranor-PGAM
|
8-[(1S,5R)-5-(2-carboxyethyl)-4-oxocyclopent-2-en-1-yl]-6-oxooctanoic acid
|
FA 16:5;O4
|
C16H22O6
|
310.141640
|
|
LMFA03010244
|
PGDM
|
9alpha,11beta-dihydroxy-15-oxo-13,14-dihydro-2,3,18,19-tetranor-prostan-1,20-dioic acid
|
FA 16:4;O5
|
C16H24O7
|
328.152205
|
|
LMFA03020087
|
Leukotriene B3
|
5S,12R-dihydroxy-6Z,8E,10E-eicosatrienoic acid
|
FA 20:3;O2
|
C20H34O4
|
338.245710
|
|
LMFA03040012
|
Lipoxin A5
|
5S,6R,15S-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid
|
FA 20:5;O3
|
C20H30O5
|
350.209325
|
|
LMFA03010248
|
PGD1-d4
|
9alpha,15S-dihydroxy-11-oxo-prost-13E-en-1-oic-3,3,4,4-d4 acid
|
|
C20H30D4O5
|
358.265733
|
|
LMFA03010245
|
13,14-dihydro-15-keto-tetranor Prostaglandin D2
|
9S-hydroxy-11,15-dioxo-2,3,4,5-tetranor-prostanoic acid
|
FA 16:3;O3
|
C16H26O5
|
298.178025
|
|
LMFA03010246
|
13,14-dihydro-15-keto-tetranor Prostaglandin E2
|
11R-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostanoic acid
|
FA 16:3;O3
|
C16H26O5
|
298.178025
|
|
LMFA03010247
|
tetranor-PGJM
|
11,15-dioxo-2,3,4,5-tetranor-9-prosten-1,20-dioic acid
|
FA 16:5;O4
|
C16H22O6
|
310.141640
|
|
LMFA03110352
|
5-F3t-IsoP
|
(E,5S)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(2Z,5Z)-octa-2,5-dienyl]cyclopentyl]-5-hydroxyhept-6-enoic acid
|
FA 20:4;O3
|
C20H32O5
|
352.224975
|
|
LMFA03080025
|
(+/-)11,12-EpETrE-d11
|
(+-)11(12)-epoxy-5Z,8Z,14Z-eicosatrienoic-16,16,17,17,18,18,19,19,20,20,20-d11 acid
|
|
C20H32O3
|
331.304190
|
|
LMFA03050033
|
(+/-)11,12-DiHETrE-d11
|
(+-)11,12-dihydroxy-5Z,8Z,14Z-eicosatrienoic-16,16,17,17,18,18,19,19,20,20,20-d11 acid
|
|
C20H23D11O4
|
349.314755
|
|
LMFA03050034
|
(+/-)14,15-DiHETrE-d11
|
14,15-dihydroxy-5Z,8Z,11Z-eicosatrienoic 16,16,17,17,18,18,19,19,20,20,20-d11 acid
|
|
C20H23D11O4
|
349.314755
|
|
LMFA03080026
|
(+/-)5,6-EpETrE-d11
|
(+/-)5(6)-epoxy-8Z,11Z,14Z-eicosatrienoic-16,16,17,17,18,18,19,19,20,20,20-d11
|
|
C20H21D11O3
|
331.304190
|
|
LMFA03080027
|
(+/-)8,9-EpETrE-d11
|
(+/-)8(9)-epoxy-5Z,11Z,14Z-eicosatrienoic-16,16,17,17,18,18,19,19,20,20,20-d11
|
|
C20H21D11O3
|
331.304190
|
|
LMFA03050035
|
(+/-)8,9-DiHETrE-d11
|
(+/-)8,9-dihydroxy-5Z,11Z,14Z-eicosatrienoic-16,16,17,17,18,18,19,19,20,20,20-d11
|
|
C20H23D11O4
|
349.314755
|
|
LMFA03010249
|
13,14-dihydro-15-keto-PGE2-d4
|
9,15-dioxo-11R-hydroxy-5Z-prostenoic 3,3,4,4-d4 acid
|
|
C20H28D4O5
|
356.250082
|
|
LMFA03010250
|
15-deoxy-delta-12,14-PGJ2-d4
|
11-oxo-prosta-5Z,9,12E,14E-tetraen-1-oic-3,3,4,4-d4 acid
|
|
C20H24D4O3
|
320.228952
|
|
LMFA03110353
|
8-isoPGF2alpha-d4
|
9alpha,11alpha,15S-trihydroxy-(8beta)-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid
|
|
C20H30D4O5
|
358.265733
|
|
LMFA03010251
|
PGB2-d4
|
9-oxo-15S-hydroxy-prosta-5Z,8(12),13E-trien-1-oic-3,3,4,4-d4 acid
|
|
C20H26D4O4
|
338.239517
|
|
LMFA03140014
|
Resolvin E1-d4
|
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic 6,7,14,15-d4 acid
|
|
C20H26D4O5
|
354.234432
|
|
LMFA03070062
|
15S-HEPE-d5
|
15S-hydroxy-5Z,8Z,11Z,13E,17Z-eicosapentaenoic-19,19,20,20,20-d5 acid
|
|
C20H25D5O3
|
323.250879
|
|
LMFA03020088
|
LTC4-d5
|
5S-hydroxy-6R-(S-glutathionyl),7E,9E,11Z,14Z-eicosatetraenoic-19,19,20,20,20-d5 acid
|
|
C30H42D5N3O9S
|
630.334686
|
|
LMFA03020089
|
LTD4-d5
|
5S-hydroxy-6R-(S-cysteinylglycinyl)),7E,9E,11Z,14Z-eicosatetraenoic-19,19,20,20,20-d5 acid
|
|
C25H35D5N2O6S
|
501.292092
|
|
LMFA03020090
|
LTE4-d5
|
5S-hydroxy-6R-(S-cysteinyl)-7E,9E,11Z,14Z-eicosatetraenoic-19,19,20,20,20-d5 acid
|
|
C23H32D5NO5S
|
457.302262
|
|
LMFA03040013
|
Lipoxin A4-d5
|
5S,6R,15S-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic-19,19,20,20,20-d5 acid
|
|
C20H27D5O5
|
357.256359
|
|
LMFA03010252
|
tetranor-PGDM-d6
|
9S-hydroxy-11,15-dioxo-2,3,4,5-tetranor-prostan-1,20-dioic-17,17,18,18,19,19-d6 acid
|
|
C16H18D6O7
|
334.189866
|
|
LMFA03000036
|
15-HEDE
|
15-hydroxy-11Z,13E-eicosadienoic acid
|
FA 20:2;O
|
C20H36O3
|
324.266446
|
|
LMFA03110354
|
8,12-iso-iPF2alpha-VI
|
5,9S,11R-trihydroxy-6E,14Z-prostadienoic acid-cyclo[8R,12S]
|
FA 20:3;O3
|
C20H34O5
|
354.240626
|